MedTrace Logo

Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates

NCT05961280 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 385

Last updated 2023-07-27

No results posted yet for this study

Summary

This study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with DCIS on biopsy and subsequently underwent mastectomy with axillary surgery to establish the need for SLNB. Furthermore, we explored the clinicopathologic features related to the upgrade to invasive breast cancer and axillary lymph node metastasis.

Conditions

  • Ductal Carcinoma in Situ

Interventions

PROCEDURE

Mastectomy with sentinel lymph node biopsy

Sponsors & Collaborators

  • Gangnam Severance Hospital

    lead OTHER

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2021-12-30
Completion
2021-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05961280 on ClinicalTrials.gov